Tumor-associated calcium signal transducer 2, also known as Trop-2 and as epithelial glycoprotein-1 antigen (EGP-1) is a protein that in humans is encoded by the TACSTD2 gene.
It transduces an intracellular calcium signal and acts as a cell surface receptor.
It is a cell surface protein that is expressed in various types of cancer.
Trop2 has been shown to play a role in cancer cell proliferation, migration, and invasion, making it an important target for cancer therapy.
Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.
Trop-2 expression was originally described in trophoblasts in the placenta and fetal lung tissues.
Its expression is also described in the normal stratified squamous epithelium of the skin, uterine cervix, esophagus, and tonsillar crypts.
Trop-2 plays a role in tumor progression by actively interacting with several key molecular signaling pathways traditionally associated with cancer development and progression.
Aberrant overexpression of Trop-2 has been described in several solid cancers, such as colorectal, renal, lung, and breast cancers, as well as rare and aggressive malignancies, e.g., salivary duct, anaplastic thyroid, uterine/ovarian, and neuroendocrine prostate cancers.
Has been observed across all breast cancer subtypes.
This antigen is the target of sacituzumab govitecan, an antibody-drug conjugate.